Odonate Therapeutics Inc Quick Ratio (ODT) starting from the third quarter 2021 to third quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Odonate Therapeutics Inc   (NASDAQ: ODT)

Odonate Therapeutics Inc 's Quick Ratio

ODT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2021, Quick Ratio fell to 3.14 below Odonate Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 412 other companies have achieved higher Quick Ratio than Odonate Therapeutics Inc in third quarter 2021. While Quick Ratio total ranking in the third quarter 2021 has deteriorated compared to the prior quarter from 1405 to 1549.

Explain Quick Ratio?
How much Cash & cash equivalents ODT´s has?
What are ODT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ODT Quick Ratio (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4		 (Sep 30 2020)
Q3
Y / Y Current Liabilities Change 6.17 % 16.02 % 32.15 % 9.26 % 15.22 %
Y / Y Cash & cash equivalent Change -49.52 % -12.19 % -13.03 % -12.85 % -7.83 %
Quick Ratio MRQ 3.14 3.71 4.02 5.81 6.6
ODT's Total Ranking # 1549 # 1405 # 1070 # 1065 # 437
Seq. Current Liabilities Change 2.18 % -10.41 % 22.24 % -5.12 % 11.66 %
Seq. Cash & cash equivalent Change -13.71 % -17.3 % -15.33 % -16.46 % 50.11 %



Quick Ratio third quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 413
Healthcare Sector # 726
Overall Market # 1549


Quick Ratio Statistics
High Average Low
20.13 3.29 0.11
(Mar 31 2018)   (Jun 30 2012)




Financial Statements
Odonate Therapeutics Inc 's Current Liabilities $ 30 Millions Visit ODT's Balance sheet
Odonate Therapeutics Inc 's Cash & cash equivalent $ 95 Millions Visit ODT's Balance sheet
Source of ODT's Sales Visit ODT's Sales by Geography


Cumulative Odonate Therapeutics Inc 's Quick Ratio

ODT's Quick Ratio for the trailling 12 Months

ODT Quick Ratio

 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months		 (Sep 30 2020)
12 Months
Y / Y Current Liabilities TTM Growth 15.59 % 18.18 % 51.25 % 108.6 % 134.34 %
Y / Y Cash & cash equivalent TTM Growth -23.43 % -11.22 % 12.3 % 62.14 % 88.44 %
Quick Ratio TTM 4.13 4.98 5.29 5.88 6.23
Total Ranking TTM # 1001 # 4394 # 4379 # 4349 # 4382
Seq. Current Liabilities TTM Growth 1.49 % 3.58 % 7.58 % 2.21 % 3.76 %
Seq. Cash & cash equivalent TTM Growth -15.83 % -2.53 % -3.2 % -3.58 % -2.41 %

Quick ratio ranking by company, industry and sector >> Back to ODT Financial Strength Comparisons >> Go to Compare ODT Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2021 to $30.30 millions, cumulative Quick Ratio decreased to 4.13 below the Odonate Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 323 other companies have achieved higher Quick Ratio than Odonate Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 1001, from total ranking during the twelve months ending second quarter 2021 at 4394.

Explain Quick Ratio?
How much Cash & cash equivalents ODT´s has?
What are ODT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 324
Healthcare Sector # 553
Within the Market # 1001


trailing twelve months Quick Ratio Statistics
High Average Low
16.95 6.78 0.43
(Mar 31 2018)   (Dec 31 2017)




Companies with similar Quick Ratio in the quarter ending Sep 30 2021, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2021 MRQ Cash & cash equivalentSep 30 2021 MRQ Current Liabilities
Bicycle Therapeutics Plc  8.60 $ 259.524  Millions$ 30.177  Millions
Opus Genetics Inc   8.58 $ 22.633  Millions$ 2.638  Millions
Y mabs Therapeutics inc   8.51 $ 215.730  Millions$ 25.359  Millions
Catalyst Pharmaceuticals Inc   8.48 $ 174.792  Millions$ 20.614  Millions
Arvinas Inc   8.46 $ 1,544.477  Millions$ 182.508  Millions
United Therapeutics Corporation  8.46 $ 2,000.400  Millions$ 236.500  Millions
Durect Corp  8.45 $ 80.796  Millions$ 9.565  Millions
Ngm Biopharmaceuticals Inc   8.44 $ 383.429  Millions$ 45.440  Millions
Schrodinger Inc   8.42 $ 597.186  Millions$ 70.938  Millions
Agios Pharmaceuticals Inc   8.41 $ 400.224  Millions$ 47.601  Millions
Inmed Pharmaceuticals Inc  8.34 $ 15.389  Millions$ 1.845  Millions
Evoke Pharma Inc   8.31 $ 11.142  Millions$ 1.341  Millions
Io Biotech Inc   8.25 $ 45.477  Millions$ 5.510  Millions
Xilio Therapeutics Inc   8.25 $ 99.767  Millions$ 12.098  Millions
Roivant Sciences Ltd   8.23 $ 2,497.330  Millions$ 303.444  Millions
Ampio Pharmaceuticals inc   8.22 $ 17.118  Millions$ 2.083  Millions
Pyxis Oncology Inc   8.08 $ 133.477  Millions$ 16.512  Millions
Phathom Pharmaceuticals Inc   8.08 $ 224.618  Millions$ 27.811  Millions
Corcept Therapeutics Inc  8.07 $ 361.331  Millions$ 44.757  Millions
Protagonist Therapeutics inc   8.03 $ 314.301  Millions$ 39.156  Millions
Verastem Inc   8.02 $ 103.416  Millions$ 12.898  Millions
Syndax Pharmaceuticals Inc   8.00 $ 229.714  Millions$ 28.712  Millions
89bio Inc   7.93 $ 157.333  Millions$ 19.845  Millions
Albireo Pharma inc   7.92 $ 262.612  Millions$ 33.149  Millions
G1 Therapeutics Inc   7.90 $ 212.089  Millions$ 26.839  Millions
Chinook Therapeutics Inc   7.81 $ 184.035  Millions$ 23.572  Millions
Ibio inc   7.76 $ 62.844  Millions$ 8.098  Millions
Inovio Pharmaceuticals Inc   7.69 $ 394.941  Millions$ 51.376  Millions
Exicure Inc   7.64 $ 60.838  Millions$ 7.965  Millions
Ocular Therapeutix Inc   7.60 $ 179.281  Millions$ 23.604  Millions

Date modified: 2026-08-29T17:39:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.